Bersanlimab BI-505|cas:1987854-08-9|西域试剂

Bersanlimab BI-505,95.0%

产品编号：Bellancom-P99473| CAS NO：1987854-08-9

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99473		￥4200.00	杭州北京（现货）
Bellancom-P99473		￥10900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Bersanlimab BI-505

产品介绍

Bersanlimab (BI-505) 是一种全人源单克隆抗体，靶向细胞间粘附分子-1 (ICAM-1 或 CD54)。Bersanlimab 具有抗癌作用。

生物活性

Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects.

体外研究

BI-505（1 ng/mL-1000 μg/mL）剂量依赖性地诱导表达 ICAM-1 的 Ramos、Raji 和 Daudi 淋巴瘤细胞的程序性细胞死亡 (PCD)。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Bersanlimab（BI-505；20 mg/kg；腹腔注射；每周两次；持续 21 天）显着减少肿瘤生长并延长动物存活期。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice injected with ARH-77 cells
Dosage:	20 mg/kg
Administration:	i.p.; twice-weekly; for 21 days
Result:	Significantly reduced tumor growth and prolonged animal survival.

体内研究

Bersanlimab（BI-505；20 mg/kg；腹腔注射；每周两次；持续 21 天）显着减少肿瘤生长并延长动物存活期。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice injected with ARH-77 cells
Dosage:	20 mg/kg
Administration:	i.p.; twice-weekly; for 21 days
Result:	Significantly reduced tumor growth and prolonged animal survival.